nach oben

Current Pulmonology Reports

Erschienen in:

01.12.2019 | Interventional Pulmonology (G Cheng, Section Editor)

Update on Management of Pleural Disease

verfasst von: Catherine L. Oberg, Adnan Majid

Erschienen in: Current Pulmonology Reports | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of review

The goal of this paper is to review and summarize the most recent updates in the management of both benign and malignant pleural diseases.

Recent findings

Multiple trials evaluating the use of non-surgical techniques for the management of pleural infection have been published in the last 5 years. Additionally, the use of tunneled pleural catheter (TPC) placement in the management of non-infectious recurrent pleural effusions is being increasingly studied. Finally, the separate use of TPC placement or talc pleurodesis as well as a combined rapid pleurodesis protocol involving both talc poudrage and TPC placement has been published in the area of symptomatic recurrent malignant pleural effusion.

Summary

Exciting advances have been made in the field of pleural disease management. In this paper, we summarize the most relevant trials, provide a list of pertinent references for review, and discuss future research directions.

Light RW. Pleural effusions. Med Clin North Am. 2011;95:1055–70.CrossRef

Semenkovich TR, Olsen MA, Puri V, Meyers BF, Kozower BD. Current state of empyema management. Ann Thorac Surg. 2018;105(6):1589–96.CrossRef

Davies HE, Davies RJ, Davies CW, et al. Management of pleural infection in adults: British Thoracic Society pleural disease guideline 2010. Thorax. 2010;65(Suppl 2):ii41–53.CrossRef

Light RW, Girard WM, Jenkinson SG, et al. Parapneumonic effusions. Am J Med. 1980;69:507e12.CrossRef

Chen, et al. Ultrasound Med. 2000;19:837–43.CrossRef

Maskell NA, Davies CW, Nunn AJ, et al. U.K. Controlled trial of intrapleural streptokinase for pleural infection. N Engl J Med. 2005;352:865e74.CrossRef

White HD, Henry C, Stock EM, Arroliga AC, Ghamande S. Predicting long-term outcomes in pleural infections. RAPID Score for Risk Stratification. Ann Am Thorac Soc. 2015;12(9):1310–6.CrossRef

•• Rahman NM, Maskell NA, West A, et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. N Engl J Med. 2011;365:518–26 This study showed that the combination of tPA and Dnase improved fluid drainage, decreased hospital length of stay, and reduced the need for surgical intervention in patients with pleural infections. CrossRef

Piccolo F, Pitman N, Bhatnagar R, Popowicz N, Smith NA, Brockway B, et al. Intrapleural tissue plasminogen activator and deoxyribonuclease for pleural infection: an effective and safe alternative to surgery. Ann Am Thorac Soc. 2014;11:1419–25.CrossRef

10.

•• Majid A, Kheir F, Folch A, et al. Concurrent intrapleural instillation of tissue plasminogen activator and DNase for pleural infection. A single-center experience. Ann Am Thorac Soc. 2016;13(9):1512–8 This showed that early administration of concurrent tPA and DNase in patients with pleural infection is feasible, safe, and effective. CrossRef

11.

Khemasuwan D, Sorensen J, Griffin DC. Predictive variables for failure in administration of intrapleural tissue plasminogen activator/deoxyribonuclease in patients with complicated parapneumonic effusions/empyema. Chest. 2018;154(3):550–6.CrossRef

12.

Redden MD, Chin TY, van Driel ML. Surgical versus non-surgical management for pleural empyema. Cochrane Database Syst Rev. 2017;3:CD010651.PubMed

13.

•• Majid A, de Lima A, Parikh M, Chee A, Fernandez-Bussy S, Kheir F. Tunneled pleural catheters for patients with chronic pleural infection and nonexpandable lung. J Bronchol Interv Pulmonol. 2019;26(2):132–6 This study showed that in patients whose surgical risk was high, TPC placement offered relief of chronic pleural infection. CrossRef

14.

Freeman RD, Ascioti AJ, Dake M, Mahidhara RS. A propensity-matched comparison of pleurodesis or tunneled pleural catheter for heart failures patients with recurrent pleural effusion. Ann Thorac Surg. 2014;97(6):1872–6.CrossRef

15.

• Walker SP, Morley AJ, Stadon L, et al. Nonmalignant pleural effusions: a prospective study of 356 consecutive unselected patients. Chest. 2017;151(5):1099–105 This prospective study of 356 patients with non-malignant pleural effusion described mortality rates of 50%, 46%, and 25% for patients with cardiac, renal, and hepatic disease, respectively. Presence of bilateral effusions and transudative effusions were both associated with a worse prognosis. CrossRef

16.

Patil M, Dhillon SS, Attwood K, Saoud M, Alraiyes AH, Harris K. Management of benign pleural effusions using indwelling pleural catheters: a systematic review and meta-analysis. Chest. 2017;151(03):626–35.CrossRef

17.

Krishnan M, Cheriyath P, Wert Y, Moritz TA. The untapped potential of tunneled pleural catheters. Ann Thorac Surg. 2015;100(06):2055–7.CrossRef

18.

Chalhoub M, Harris K, Castellano M, Maroun R, Bourjeily G. The use of the PleurX catheter in the management of non-malignant pleural effusions. Chron Respir Dis. 2011;8(03):185–91.CrossRef

19.

•• Majid A, Kheir F, Fashjian M, et al. Tunneled pleural catheter placement with and without talc poudrage for treatment of pleural effusions due to congestive heart failure. Ann Am Thorac Soc. 2016;13(02):212–6 This retrospective cohort study compared the use of medical thoracoscopy, talc poudrage, and TPC placement (group 1) to TPC placement alone in patients with recurrent effusion from CHF. All patients experienced improvement in dyspnea as well as decreased hospital readmission rates; however, rates of successful pleurodesis were significantly increased in group 1. PubMed

20.

Bramley K, DeBiasi E, Puchalski J. Indwelling pleural catheter placement for nonmalignant pleural effusions. Semin Respir Crit Care Med. 2018;39(6):713–9.CrossRef

21.

Chen A, Massoni J, Jung D, Crippin J. Indwelling tunneled pleural catheters for the management of hepatic hydrothorax. A pilot study. Ann Am Thorac Soc. 2016;13(06):862–6.CrossRef

22.

Kniese C, Diab K, Ghabril M, Bosslet G. Indwelling pleural catheters in hepatic hydrothorax: a single-center series of outcomes and complications. Chest. 2019;155(2):307–14.CrossRef

23.

•• Shojaee S, Rahman N, Haas K, et al. Indwelling tunneled pleural catheters for refractory hepatic hydrothorax in patients with cirrhosis: a multicenter study. Chest. 2019;155(3):546–53 This is a retrospective multicenter study of patients with hepatic hydrothorax examining outcomes of those with TPC’s in place. In this population there was a 10% infection rate as well as a 2.5% rate of mortality. Twenty-eight percent achieved pleurodesis. CrossRef

24.

McCracken DJ, Porcel JM, Rahman NM. Malignant pleural effusions: management options. Semin Respir Crit Care Med. 2018;39:704–12.CrossRef

25.

•• Bibby AC, Dorn P, Psallidas I, Porcel JM, Janssen J, Froudarakis M, et al. ERS/EACTS statement on the management of malignant pleural effusions. Eur Respir J. 2018;52(1). These society guidelines focus on optimum management of symptomatic MPE, management of trapped lung in MPE, management of loculated MPE, prognostic factors in MPE, whether there is a role for oncological therapies prior to intervention for MPE and whether a histological diagnosis is always required in MPE.):1800349.CrossRef

26.

Feller-Kopman DJ, Reddy CB, DeCamp MM, Diekemper RL, Gould MK, Henry T, et al. Management of malignant pleural effusions. An Official ATS/STS/STR Clinical Practice Guideline. Am J Respir Crit Care Med. 2018;198(7):839–49.CrossRef

27.

•• Thomas R, Fysh ETH, Smith NA, et al. Effect of an indwelling pleural catheter vs talc pleurodesis on hospitalization days in patients with malignant pleural effusion: The AMPLE Randomized Clinical Trial. JAMA. 2017;318(19):1903–12 This trial randomized patients with MPE to receive either TPC or talc slurry pleurodesis. While both the TPC and pleurodesis groups had significant improvements in dyspnea and quality of life scores, those who received a TPC had fewer overall hospital days from post-procedure to death and required fewer further invasive pleural drainages. CrossRef

28.

Bhatnagar R, Keenan EK, Morley AJ, Kahan BC, Stanton AE, Haris M, et al. Outpatient talc administration by indwelling pleural catheter for malignant effusion. N Engl J Med. 2018;378(14):1313–22 Patients with MPE and TPC placement were randomized to receive either outpatient talc slurry instillation or placebo. In addition to increased rates of pleurodesis, the talc group had improved quality of life measures and symptom scores with no increased number of adverse outcomes. CrossRef

29.

• Reddy C, Ernst A, Lamb C, et al. Rapid pleurodesis for malignant pleural effusions: a pilot study. Chest. 2011;139(6):1419–23 Patients with recurrent, symptomatic MPEs underwent medical thoracoscopy with placement of a TPC and talc poudrage. Both hospital length of stay and duration of TPC use was significantly reduced compared to historical controls. CrossRef

30.

Folch E, Santacruz JF. Rapid pleurodesis: an outpatient alternative. Chest. 2011;140(6):1665–6.CrossRef

31.

•• Muruganandan S, Azzopardi M, Fitzgerald DB, et al. Aggressive versus symptom-guided drainage of malignant pleural effusion via indwelling pleural catheters (AMPLE-2): an open-label randomised trial. Lancet Respir Med. 2018;6(9):671–80 This study randomized patients with MPE and TPC to daily drainage or symptom-guided drainage. While there was no difference in symptom control between the groups, 37% of those with daily drainage experienced spontaneous pleurodesis versus only 11% in the symptom-guided group. CrossRef

32.

Wahidi MM, Reddy C, Yarmus L, Feller-Kopman D, Musani A, Shepherd RW, et al. Randomized trial of pleural fluid drainage frequency in patients with malignant pleural effusions. The ASAP Trial. Am J Respir Crit Care Med. 2017;195(8):1050–7.CrossRef

33.

• Davies HE, Mishra EK, Kahan BC, et al. Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial. JAMA. 2012;307(22):2383–9 In this unblinded randomized controlled trial, patients with MPE were randomized to either TPC placement or chest tube with talc slurry pleurodesis. There was no significant difference between TPCs and talc pleurodesis at relieving patient-reported dyspnea. CrossRef

34.

Penz ED, Mishra EK, Davies HE, Manns BJ, Miller RF, Rahman NM. Comparing cost of indwelling pleural catheter vs talc pleurodesis for malignant pleural effusion. Chest. 2014;146(4):991–1000.CrossRef

35.

• Olfert JA, Penz ED, Manns BJ, et al. Cost-effectiveness of indwelling pleural catheter compared with talc in malignant pleural effusion. Respirology. 2017;22(4):764–70 Using the TIME2 data, the authors found that TPC placement was more cost-effective than talc pleurodesis in patients with limited survival (< 14 weeks), though this was negated if they required significant nursing care. CrossRef

36.

Fysh ETH, Tremblay A, Feller-Kopman D, Mishra EK, Slade M, Garske L, et al. Clinical outcomes of indwelling pleural catheter-related pleural infections: an international multicenter study. Chest. 2013;144(5):1597–602.CrossRef

37.

Iyer NP, Reddy CB, Wahidi MM, Lewis SZ, Diekemper RL, Feller-Kopman D, et al. Indwelling pleural catheter versus pleurodesis for malignant pleural effusions. A systematic review and meta-analysis. Ann Am Thorac Soc. 2019;16(1):124–31.CrossRef

38.

Safety and Effectiveness of a New Pleural Catheter for Symptomatic, Recurrent, MPEs Versus Approved Pleural Catheter (SWIFT). https://clinicaltrials.gov/ct2/show/NCT02649894; Last accessed 17 July 2019.

39.

Popowicz N, Bintcliffe O, De Fonseka D, et al. Dose de-escalation of intrapleural tissue plasminogen activator therapy for pleural infection. The Alteplase Dose Assessment for Pleural Infection Therapy Project. Ann Am Thorac Soc. 2017;14(6):929–36.CrossRef

40.

Bhatnagar R, Laskawiec-Szkonter M, Piotrowska HE, Kahan BC, Hooper CE, Davies HE, et al. Evaluating the efficacy of thoracoscopy and talc poudrage versus pleurodesis using talc slurry (TAPPS trial): protocol of an open-label randomised controlled trial. BMJ Open. 2014;4(11):e007045.CrossRef

Titel: Update on Management of Pleural Disease
verfasst von: Catherine L. Oberg
Adnan Majid
Publikationsdatum: 01.12.2019
Verlag: Springer US
Erschienen in: Current Pulmonology Reports / Ausgabe 4/2019
Elektronische ISSN: 2199-2428
DOI: https://doi.org/10.1007/s13665-019-00242-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Update on Management of Pleural Disease

Abstract

Purpose of review

Recent findings

Summary

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin

Springer Medizin

Abstract

Purpose of review

Recent findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin